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Abstract
Background: Pre-eclampsia, a syndrome of hypertension and proteinuria, is a major cause of
maternal and perinatal morbidity and mortality. Accurate prediction of pre-eclampsia is important,
since high risk women could benefit from intensive monitoring and preventive treatment.
However, decision making is currently hampered due to lack of precise and up to date
comprehensive evidence summaries on estimates of risk of developing pre-eclampsia.
Methods/Design:  A series of systematic reviews and meta-analyses will be undertaken to
determine, among women in early pregnancy, the accuracy of various tests (history, examinations
and investigations) for predicting pre-eclampsia. We will search Medline, Embase, Cochrane
Library, MEDION, citation lists of review articles and eligible primary articles and will contact
experts in the field. Reviewers working independently will select studies, extract data, and assess
study validity according to established criteria. Language restrictions will not be applied. Bivariate
meta-analysis of sensitivity and specificity will be considered for tests whose studies allow
generation of 2 × 2 tables.
Discussion: The results of the test accuracy reviews will be integrated with results of effectiveness
reviews of preventive interventions to assess the impact of test-intervention combinations for
prevention of pre-eclampsia.
Background
Pre-eclampsia belongs to a group of hypertensive disor-
ders in pregnancy, that can be divided into gestational
hypertension, chronic hypertension, pre-eclampsia, and
pre-eclampsia superimposed on chronic hypertension.
Hypertension is a common medical complication during
pregnancy. It is usually defined as systolic blood pressure
of at least 140 mmHg and/or diastolic blood pressure of
at least 90 mmHg. Pre-eclampsia is defined as hyperten-
sion accompanied by proteinuria first detected after 20
weeks gestation. Proteinuria is defined as at least 300 mg
protein in a 24 hour urine collection (or ≥ 1 + dipstick (30
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mg/dL) in a single urine sample) [1-3]. In the past, other
components such as oedema or a rise in systolic and/or
diastolic blood pressure have been included in the defini-
tion of pre-eclampsia. However, these components do not
define a group at risk of poor outcome[4,5]. Oedema is
also a common feature of normal pregnancy. Women
with mild pre-eclampsia generally have no symptoms.
However, women with severe pre-eclampsia (usually RR ≥
160/110 mmHg and/or proteinuria ≥ 2–5 g/24 hours)
may have signs and symptoms such as renal insufficiency
(reduced urinary volume, raised serum creatinine), liver
disease (upper abdominal pain, elevated liver enzymes),
neurological disturbances (headache, visual disturbances,
exaggerated tendon reflexes, convulsions (eclampsia)),
and haematological disturbances (thrombocytopenia,
disseminated intravascular coagulation, haemolysis) [1-
3].
The precise aetiology of pre-eclampsia is still unknown.
Factors that appear to have a role include the placenta,
maternal immune response, genetic predisposition, and
maternal vascular disease [6]. The central cause of pre-
eclampsia lies within the placenta, and resolution of pre-
eclampsia starts with the removal of the placenta at deliv-
ery. Both abnormal implantation and excessive placental
tissue have been implicated as the underlying pathology
in pre-eclampsia [7,8]. Failure of the normal invasion of
throphoblast cells leads to maladaptation of maternal spi-
ral arterioles in the uterus, resulting in small diameter,
high resistance blood vessels that are unable to meet the
increasing demand for blood supply to the placenta [9].
On the other hand, reduced perfusion may exist in large
normally implanted placentas, such as in multiple preg-
nancies. Implantation of the placenta and vascular
changes are completed by 20–22 weeks gestation [9]. So
although pre-eclampsia is usually diagnosed in the second
half of pregnancy, damage has already occurred at an ear-
lier stage of pregnancy. These changes may lead to altera-
tions of products released from the placenta into the
maternal circulation, which then may be used as early bio-
chemical markers for disease.
Normal pregnancy requires adaptation of the maternal
immune response, so that the foetus and placenta, being
partly allogenic, are not rejected. In pre-eclampsia, this
adaptation may be inadequate in a first pregnancy with a
new partner (and limited sperm exposure), while in sub-
sequent pregnancies with the same partner the risk is
lower [6,10,11]. A miscarriage or induced abortion pro-
vide some protection, confirming immune adaptation
theories [12]. Risk factors associated with pre-eclampsia
include maternal diabetes, [13,14] chronic hyperten-
sion,[13,14] renal disease,[15] thrombophilias,[16,17]
and autoimmune disorders [18]. Obstetric factors associ-
ated with high risk are multiple pregnancies,[19] previous
pre-eclampsia, and molar or hydropic pregnancies [6,20].
Other risk factors are first pregnancy,[6,20] extremes of
age,[11] and obesity [21]. A family history of pre-eclamp-
sia may suggest a genetic predisposition [6,20].
Hypertensive disorders remain one of the largest single
causes of maternal and foetal mortality and morbidity.
Depending upon the region, between 9.1% (Africa, Asia),
16.1% (developed countries), and 25.7% (Latin America)
of maternal deaths can be accounted for by these disor-
ders [22]. Up to 18% of foetal deaths are associated with
hypertensive disorders [23]. Complications for the
women include coagulopathy, renal failure and stroke.
For the baby they include preterm delivery and intra uter-
ine growth restriction,[23] which are associated with
increased risk of developmental delay and chronic dis-
eases in childhood. In the long term, women and foetuses
affected by these disorders may be prone to cardiovascular
disease in adult life [24-28]. The vast majority of these
complications are related to pre-eclampsia.
Several tests have been purported to predict pre-eclampsia
but the underlying evidence often lacks quality and/or
precision. Accurate prediction of pre-eclampsia is impor-
tant, because intensive monitoring and administration of
early treatment with e.g. aspirin [29] can be more selec-
tively targeted at high-risk women, making timely inter-
vention easier and possibly more cost-effective. This may
prevent some of the mortality and morbidity. However,
decision making is currently hampered due to lack of up
to date and comprehensive evidence summaries on esti-
mates of risk of developing pre-eclampsia.
Methods/Design
Objective
This research project is undertaken to meet the following
objective: to determine, among women in early preg-
nancy, the accuracy of various tests (history, examination,
investigations) for predicting the later development of
pre-eclampsia.
Search strategy
Literature will be identified using
• general health and biomedical bibliographies:
MEDLINE (PubMED), EMBASE (Ovid)
• specialised electronic databases: The Cochrane Library
(DARE, CCTR), MEDION
• contact with experts, including the Cochrane Pregnancy
and Childbirth Group
• citation lists of review articles and papers that will be eli-
gible for the reviews in this project.BMC Pregnancy and Childbirth 2006, 6:29 http://www.biomedcentral.com/1471-2393/6/29
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In a single comprehensive search we will aim to find all
primary studies reporting on the accuracy of any test
(combinations) used to predict pre-eclampsia. We will
combine search terms related to pre-eclampsia with meth-
odological filters for identification of aetiologic and diag-
nostic test studies (table 1) [30-32]. All databases will be
searched from inception. Experienced clinical librarians
will perform the searches and their updates. No language
restrictions will be applied. A comprehensive master data-
base using Citation Manager 10.0 software will be estab-
lished incorporating results of all searches.
Inclusion criteria
The study inclusion criteria are:
Population
Any pregnant women in primary, secondary or tertiary
care, at any level of risk of developing pre-eclampsia. Stud-
Table 1: Search strategy to identify citations on tests used to predict pre-eclampsia
MEDLINE
1. preeclamp* OR eclamp* OR pre-eclamp* OR (pre AND eclamp*) OR (pregnan* AND hypertens*)
2. ("Eclampsia"[MeSH] OR "Gestosis, EPH"[MeSH] OR ("Hypertension"[MeSH] AND "Pregnancy"[MeSH]))
3. "Sensitivity and Specificity"[MeSH] OR predict* OR diagnose* OR diagnosi* OR diagnost* OR accura*
(1 OR 2) AND 3 (diagnosis)
4. (((((("cohort studies"[mh] OR "case-control studies"[MeSH Terms]) OR "risk"[mh]) OR "epidemiologic factors"[MeSH Terms]) OR 
("odds"[tw] AND "ratio*"[tw])) OR ("relative"[tw] AND "risk"[tw])) OR ("case"[tw] AND "control*"[tw]))
(1 OR 2) AND 4 (aetiology)
EMBASE
1. exp "ECLAMPSIA AND PREECLAMPSIA"/
2. exp PREGNANCY/
3. exp hypertension/
4. 2 and 3
5. 1 or 4
6. (preeclamp$ or eclamp$ or pre-eclamp$ or (pre and eclamp$) or (pregnan$ and hypertens$)).mp.
7. (sensitiv$ or detect$ or accura$ or specific$ or reliab$ or positive or negative or diagnos$).mp. or di.fs.
8. 5 or 6
9. 7 and 8 (diagnosis)
10. cohort analysis/
11. exp risk/
12. (odds$ adj ratio$).mp.
13. (relative adj risk).mp.
14. case control study/
15. (case$ adj control$).mp.
16. (causa$ or predispos$).mp.
17. or/10–16
18. 5 or 6
19. 17 and 18 (aetiology)
Cochrane Library
Set 1
1. preeclamp* OR eclamp* OR pre-eclamp* OR (pre AND eclamp*) OR (pregnan* AND hypertens*) in All Fields in all procucts
Set 2
2. MeSH descriptor Eclampsia explode all trees in MeSH products
3. MeSH descriptor Hypertension explode all trees in MeSH products
4. MeSH descriptor Pregnancy explode all trees in MeSH products
5. (#2 OR (#3 AND #4))
Set 3
6. MeSH descriptor Sensitivity and Specificity explode all trees in MeSH products
7. Predict* OR diagnose* OR diagnosi* OR diagnost* OR accura* in All Fields
8. (#6 OR #7)
(1 OR 2) AND 3 (diagnosis)
Set 4
1. MeSH descriptor Cohort Studies explode all trees in MeSH products
2. MeSH descriptor Case-Control Studies explode all trees in MeSH products
3. MeSH descriptor Risk explode all trees in MeSH products
4. MeSH descriptor Epidemiologic Factors explode all trees in MeSH products
5. ((odds AND ratio) OR (relative AND risk) OR (case AND control)) in All Fields in all products
6. (#1 OR #2 OR #3 OR #4 OR #5)
(1 OR 2) AND 4 (aetiology)BMC Pregnancy and Childbirth 2006, 6:29 http://www.biomedcentral.com/1471-2393/6/29
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ies will be included that tested women at risk of develop-
ing pre-eclampsia before 25 weeks of gestation. When
gestational age at the time of the index test varies the
mean gestational age as calculable from the descriptive
statistics must be less than 25 weeks. When gestational age
is unclear the study will be excluded.
Setting
Any setting including general practice, midwifery, outpa-
tient clinics, or based on national or regional registers.
Study design
Diverse study designs will be included such as prospective
cohorts, historic cohorts, and (nested) case-control stud-
ies, all of which may be matched or unmatched on differ-
ent variables. Studies must report results so that a 2 × 2
table cross classifying abnormal and normal test results
and the occurrence or non-occurrence of pre-eclampsia
can be calculated. We will exclude all cross-sectional stud-
ies in which the distribution of a non-stable indicator
(often a blood constituent) among women with pre-
eclampsia was compared to that of non-pre-eclamptic
women.
Predictive tests (index tests)
Tests used for the prediction of pre-eclampsia will be pri-
oritised on the basis of clinical relevance and after consul-
tation with persons knowledgeable of NHS needs (we will
consult particularly with the NHS Antenatal Sourcing
Subgroup).
Reference standard
Pre-eclampsia, using a variety of definitions. Pre-eclamp-
sia is defined as hypertension (≥ 140/90 mmHg) with
proteinuria (total protein of ≥ 300 mg in a 24 hour urine
collection, or ≥ 30 mg/dL in a single sample of urine, or ≥
1+ on a dipstick) developing for the first time after 20
weeks gestation, with or without generalised oedema. For
women with chronic hypertension, pre-eclampsia is
defined as a sudden worsening of hypertension and/or
proteinuria, or other signs and symptoms of pre-eclamp-
sia after 20 weeks gestation. When authors do not provide
details of how pre-eclampsia was verified, pre-eclampsia
rates as reported will be accepted. At the stage of data-
extraction, the extent that pre-eclampsia definition com-
plies with recent consensus will be assessed. All studies
that compare a test or strategy with a reference standard
according to international standards or variations of the
definition, in pregnant women will be included [1-3].
Subgroups
Severe pre-eclampsia is defined as hypertension (systolic
blood pressure ≥ 160 mmHg and/or diastolic blood pres-
sure ≥ 110 mmHg) with proteinuria (total protein of ≥ 2.0
gram in a 24 hour urine collection, or ≥ 3+ on a dipstick).
A distinction will be made between early onset (< 34
weeks gestation) and late onset (≥ 34 weeks gestation)
pre-eclampsia.
Study selection process
The study selection process will consist of three steps.
Firstly, titles and/or abstracts of all citations in the master
database (that is, irrespective of test type) will be assessed
by one reviewer. If a citation is considered potentially rel-
evant, the full-text paper will be retrieved for further con-
sideration. Reviewers will be instructed to include any
citation in case of doubt, thus enhancing the sensitivity of
the initial selection step. Secondly, for each particular
review, a search based on keywords and text words in titles
and abstracts in the master database will be performed to
find all studies on the test at issue. Another reviewer will
scrutinise titles and/or abstracts of studies on the test at
issue to ensure independent duplicate selection. Only
papers judged irrelevant twice will not be ordered as full-
text papers and all other papers will be retrieved. Thirdly,
inclusion will be performed independently by two review-
ers assessing against the selection criteria detailed above.
Disagreements will be resolved either by consensus or by
arbitration by a third reviewer when consensus cannot be
reached.
Data extraction
Clinical, methodological and statistical data extraction
will be conducted independently in duplicate using a pre-
Table 2: Tests for hypertensive disorders in pregnancy
History Risk factors e.g. nulliparity, new partner, hypertension on oral contraceptives, pre-existing diabetes, renal disease, chronic 
hypertension, parity
Examination Blood pressure (systolic and diastolic and mean arterial pressure), peripheral oedema, body mass index, waist circumference, 
hip:waist ratio
Investigations
Biochemical Serum uric acid, urinary calcium excretion, urinary albumin-creatinine and calcium-creatinine ratios, microalbuminuria, 
fibronectin, spot proteinuria, 24-hour urinary protein levels
Haemodynamic Pressor response to various forms of stimuli e.g., supine "rollover", isometric exercise, passive tilting, uterine artery Doppler
Haematological Antithrombin III, platelet count, haemoglobin, haematocrit, fibrinogen
Other tests Thrombomodulin, endothelin-1, plasminogen activator inhibitor, free fatty acids, atrial natriuretic peptide, angiotensin II 
infusion, platelet angiotensin II binding site density, öhCG, õFP, fasting insulin levelsBMC Pregnancy and Childbirth 2006, 6:29 http://www.biomedcentral.com/1471-2393/6/29
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designed and piloted form that will vary only slightly
between different reviews.
The following data will be extracted from each included
study: first author; year of publication; setting; number of
participating centres; country of investigation; admission
criteria for participants; baseline characteristics; inclusion
period; study design characteristics; details of the index
test measurement; details of the citation standard; num-
bers of included subjects, proportion dropped out, pro-
portion uninterpretable/indeterminate/intermediate test
results; (pre-specified) cut-off values; incidence of pre-
eclampsia within the study population; (mean) time of
onset and severity of pre-eclampsia; numbers of subjects
on which to base 2 × 2 data tables or necessary data for the
construction of a 2 × 2 data table; correlation coefficients
between tests; financial support of industry.
Again, disagreements between reviewers will be resolved
by consensus or by arbitration by a third reviewer when
consensus cannot be reached. In case of serial index test
measurements during pregnancy a 2 × 2 table will be con-
structed for each serial measurement. Where multiple
publications of the same study will be identified, each
publication will be examined to ensure that all relevant
data for that particular study are recorded. Only the most
complete report will be used for extracting results.
Pairs of data-extraction forms will be checked for discrep-
ancies. After resolution of disagreements, data will be
entered into a dedicated SPSS database. Relevant variables
will be checked using descriptive statistics to detect
implausible values or outliers. Extreme or outlying values
will be checked against the original data extraction forms
and against the original publications if necessary to fur-
ther exclude the possibility of data-entry errors.
Quality assessment
Quality items will be included in the data extraction form.
The following aspects of methodological and reporting
quality of included test accuracy studies will be
assessed[33,34].
• study design;
• consecutive recruitment/random sample;
• blinding of test results (both index and reference tests);
• greater than 90% verification of diagnosis;
• incidence of pre-eclampsia less than 4%;
• prospective data collection;
• adequate description of index test;
• adequate reference standard.
Note that items on study design and incidence are not
strictly related to internal validity, but help the reader to
put the findings in context. Study quality will be assessed
independently by two reviewers. Any disagreements will
be resolved by consensus or by arbitration by a third
reviewer, when consensus cannot be reached.
The following items will be assessed using the three crite-
ria listed under each item:
• Consecutive recruitment
Yes – when the test explicitly states consecutive or random
sampling;
No – when the description is explicit but words indicating
consecutive or random sampling are missing;
Unclear – otherwise.
• Blinding of test results (index test or reference test)
Yes – adequate blinding will be judged present when the
text explicitly states that the results of each test were inter-
preted unaware (blind, masked) of the results of the other
test or when it may be inferred that they were interpreted
before the other test results were available (for example
the index test result in prospective cohort studies);
No – inadequate blinding will be judged present if it is
clear from the text that neither test result was interpreted
under blind conditions;
Unclear – otherwise.
• Verification of diagnosis
Yes – adequate verification of diagnosis will be judged
present where at least 90% of the women originally sub-
jected to the index test and fulfilling the inclusion criteria
were followed up and had verification by the reference
standard;
No – inadequate where the follow up percentage is below
90%;
Unclear – where the numbers of women excluded or lost
to follow up are not calculable;
• Incidence of pre-eclampsia < 4%
Yes – unselected (low risk) patient spectrum where inci-
dence of pre-eclampsia less than or equal to 4%;*BMC Pregnancy and Childbirth 2006, 6:29 http://www.biomedcentral.com/1471-2393/6/29
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No – selected patient spectrum where incidence of pre-
eclampsia is greater than 4%;
Unclear – when the incidence cannot be derived from the
article (for example in case control studies).
We intend to dichotomise the item "incidence of pre-
eclampsia" using an incidence cut-off value of 4% in
cohort studies (and based on the underlying cohort in
nested case-control analyses where possible). This seems
wise because we found that in cohort studies with more
than 30,000 women, which reflect more or less unselected
populations, the incidence of pre-eclampsia varies
between 1.3 and 3.2% [35-37]
• Prospective data collection
Yes – adequate when it is clear that the research protocol
for the study has been written before data collection took
place (prospective);
No – inadequate when there is retrospective data collec-
tion or there is a mixture of prospective and retrospective
data collection;;
Unclear – otherwise.
• Adequate description of index test
Yes – if the gestational age at the time of testing, type of
test (e.g. assay/manufacturer, specified for each test) and
cut-off level are reported;
No – if nothing is reported;
Unclear – omission of one or more items.
• Adequate reference standard
Yes – if strictly in accordance with current internationally
accepted standards of definition of pre-eclampsia;
No – when the definition of pre-eclampsia includes other
items such as a rise in systolic or diastolic blood pressure
or for example hyperuricaemia or oedema, or when crite-
ria are more loose or stringent;
Unclear – otherwise.
Adequacy of the reference standard for studies that report
on severe pre-eclampsia as an outcome will be based on
the definition of severe pre-eclampsia.
Methods of statistical analysis
The main focus of each review will be a summary estimate
of predictive accuracy as expressed by its sensitivity and
specificity. A secondary aim is to identify (clinically rele-
vant) sources of heterogeneity. If the calculation of a sum-
mary estimate is judged not meaningful, individual study
results will be depicted using forest plots of sensitivity and
specificity with their 95% confidence intervals, and using
receiver operating characteristics (ROC) plots ("1-specifi-
city" against "sensitivity").
Data exploration and statistical analysis
In each review, we will use forest plots and ROC plots to
display the precision by which sensitivity and specificity
has been measured in each study, and to illustrate the var-
iation in estimates between studies. Ninety-five percent
confidence intervals (95% CIs) will be calculated using
the exact binomial method, according to Wilson[38].
Extreme values, outliers, and threshold phenomena (data
points on a typical convex ROC curve) will be explored.
We will consider the use of a bivariate meta-regression
model to meta-analyse estimates of sensitivity (true posi-
tives/(true positives + false negatives) and specificity (true
negatives/(true negatives + false positives) [39,40]. Rather
than using a single outcome measure per study, like the
diagnostic odds ratio in the summary ROC approach, the
bivariate model preserves the two-dimensional nature of
diagnostic data by directly analysing the logit transformed
sensitivity log(sens/(1-sens)) and specificity log(spec/(1-
spec)) of each study in a single model. This model esti-
mates and incorporates the correlation that may exist
between logit sensitivity and logit specificity within stud-
ies due to possible differences in threshold between stud-
ies. The bivariate model uses a random effects approach
for both sensitivity and specificity, allowing for heteroge-
neity beyond chance due to clinical or methodological
differences between studies. In addition, the model
acknowledges the difference in precision by which sensi-
tivity and specificity have been measured in each study.
This means that studies with a larger number of patients
with the target condition receive more weight in the calcu-
lation of the summary estimate of sensitivity, while stud-
ies with more patients without the target condition are
more influential in the pooling of specificity. A standard
correction of adding 0.5 to all four cells of the 2 × 2 table
will be applied when either sensitivity or specificity is
100%. The model produces the following results: a ran-
dom effect estimate of the mean sensitivity and specificity
with corresponding 95% confidence intervals, the
amount of between-study variation for sensitivity and spe-
cificity separately, and the strength and shape of the corre-
lation between sensitivity and specificity. All the results
will be transformed back (anti-logit) to the original scale,
and plotted in ROC space. Where possible, covariates will
be added to the model to test explicitly whether either sen-
sitivity, or specificity, or both are different in studies with
and without the characteristic. When possible the analysis
aims to estimate valid measures of predictive accuracy tak-
ing into account confounding by any methodologicalBMC Pregnancy and Childbirth 2006, 6:29 http://www.biomedcentral.com/1471-2393/6/29
Page 7 of 8
(page number not for citation purposes)
flaws. In a first instance, attempts will be always made to
quantify the extent to which the accuracy measures varied
by clinical subgroups, such as early versus late testing.
STATA/SE 9.0 (StataCorp, Texas, USA) will be used for cal-
culations except to fit the various bivariate models for
which the Proc Mixed procedure in SAS version 9.1 for
Windows (SAS Institute Inc, Cary, NC, USA) will be used.
Discussion
The methodology of systematic reviews of test accuracy is
difficult and still developing. In contrast to the field of
randomised trials, didactic guidelines on conducting pri-
mary diagnostic studies and systematic reviews of diag-
nostic studies have only recently been developed [41-43].
Also more recently, a quality tool for diagnostic studies
has been developed [44]. Older studies tend to report less
accurately than more recent studies, which does not nec-
essarily prove that older studies executed less rigorously
than more recent studies. Therefore, incorporating meth-
odological and reporting quality of primary studies in
analyses of systematic reviews may be difficult. However,
shortcomings in design and conduct can affect estimates
of diagnostic accuracy, but the magnitude of the effect
may vary from one situation to another [45].
This project is part of a more comprehensive research
project concerning prediction and prevention of pre-
eclampsia. The results of the accuracy reviews will be inte-
grated with results of effectiveness reviews of preventive
interventions to assess cost-effectiveness of strategies (test-
intervention combinations) for prediction and preven-
tion of pre-eclampsia. Results will probably be available
in 2007.
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